Texas Attorney General Ken Paxton has launched a lawsuit against pharmaceutical giants Sanofi and Bristol-Myers Squibb, alleging they deliberately concealed critical information about their blockbuster drug Plavix being ineffective for certain racial groups. The lawsuit, filed on November 20, claims the companies violated state fraud prevention and consumer protection laws while raking in billions from a medication that failed many of the patients who needed it most.
At the heart of the legal action are accusations that the companies knew Plavix — prescribed to prevent heart attacks, strokes, and blood clots — had diminished or zero effectiveness in Black, East Asian, and Pacific Islander patients but failed to disclose this critical information to doctors or patients.
Life-Threatening Omissions
The blood thinner, known generically as clopidogrel bisulfate, works by inhibiting platelet aggregation in the bloodstream. But for specific racial groups, the drug’s therapeutic effect was substantially reduced or entirely absent, potentially leaving vulnerable patients without the protection they believed they were receiving.
“It’s despicable how Big Pharma puts lives at risk by refusing to be honest with patients,” Paxton stated in the announcement. “We are going to make Sanofi and Bristol-Myers Squibb pay a heavy cost for their utter lack of regard or concern for Americans and the company’s clear violations of Texas law.”
What makes this case particularly troubling? The lawsuit contends that while patients believed they were protected from potentially fatal cardiovascular events, many were essentially taking an ineffective medication due to genetic factors the companies allegedly knew about but didn’t properly disclose.
Profits Over Patients
The companies reportedly generated billions in revenue while marketing Plavix as universally effective. According to the Attorney General’s allegations, this marketing strategy continued even as evidence mounted about the drug’s variable effectiveness across different populations.
Medical experts have long recognized that certain medications can have varying effectiveness based on genetic factors that sometimes correlate with race or ethnicity. The lawsuit doesn’t challenge the legitimate use of Plavix in populations where it’s effective, but rather focuses on the companies’ alleged failure to warn about known limitations.
Paxton emphasized that the lawsuit serves as a warning shot to the pharmaceutical industry. “Every healthcare and pharmaceutical company should be put on notice that anyone who endangers the health of Americans absolutely will be held accountable,” he warned.
Neither Sanofi nor Bristol-Myers Squibb had issued public responses to the allegations as of press time.
The case represents one of several recent efforts by state attorneys general to hold pharmaceutical companies accountable for alleged misconduct, particularly regarding disclosure of risks and limitations of widely prescribed medications. For patients who relied on Plavix for their cardiovascular health, the outcome could determine whether they were unknowingly gambling with their lives while pharmaceutical executives counted their profits.
